Publications by authors named "Nabil Andrawis"
Article Synopsis
- Pegozafermin, a new drug being tested for severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis, was evaluated in a phase 2 trial with 85 participants over 8 weeks.
- Results showed that patients taking pegozafermin had a significant reduction in triglycerides (57.3%) compared to those on placebo (11.9%), achieving the trial's main goal.
- Secondary outcomes also indicated improvements in related cholesterol levels and liver fat, with no serious side effects linked to the drug, suggesting it may be a strong candidate for further testing in a phase 3 trial.
Aim: To evaluate the tolerability, safety and pharmacodynamics of different dose-escalation schemes of the oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist danuglipron.
Materials And Methods: This Phase 2a, double-blind, placebo-controlled, parallel-group study randomly assigned adults with type 2 diabetes (T2D) treated with metformin to placebo or danuglipron (low [5-mg] or high [10-mg] starting dose, with 1- or 2-week dose-escalation steps, to target doses of 80, 120 or 200 mg twice daily [BID]) and adults with obesity without diabetes to placebo or danuglipron 200 mg BID.
Results: Participants with T2D (n = 123, mean glycated haemoglobin [HbA1c] 8.
Background: Per treatment guidelines, resistant hypertension is defined as uncontrolled blood pressure (BP) while taking 3 concomitant antihypertensives (AHTs) or controlled BP while taking ≥4 AHTs. Characteristics, AHT therapy use, and BP control were analyzed in US patients with hypertension who were prescribed ≥3 classes of AHT medications.
Methods: This retrospective analysis of the Optum® Electronic Health Record Database evaluated patients ≥18 years of age with a diagnosis of hypertension classified based on the number of prescribed AHT medication classes (3, 4, or ≥5).